Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Sangamo BiOSciences, Inc. (SGMO) Publishes Study In Nature Medicine Demonstrating Use Of ZFN Technology To Develop Safer And More Effective Cancer Treatments 2 comments
    Apr 3, 2012 2:08 PM | about stocks: SGMO

    Sangamo BioSciences announced the publication of a preclinical study that demonstrates the use of zinc finger nucleases (ZFNs) for engineering safer and more potent cancer immunotherapies. Published in Nature Medicine, the study advances the development of novel, cell-based therapies for treating a wide range of cancers.

    Chiara Bonini, M.D., head of the experimental hematology unit at San Raffaele Hospital in Milan, performed the studies in her laboratory in collaboration with Luigi Naldini, head of TIGET at San Raffaele Hospital, and Sangamo scientists. Bonini presented the data at the opening session of the 2012 Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) in Geneva, Switzerland. The work's importance has been indicated by the receipt of the Van Bekkum Award, which is the most prestigious EBMT award for the best abstract submitted to the physician's program.

    The study's data represent a notable advance in maximizing the potential safety and efficacy of adoptive T-cell therapies for cancer. While it is presently possible to reprogram immune system cells to preferentially recognize and kill tumors, several hurdles still exist that limit the potential of this approach. ZFN-based genome editing allows specific modification of these redirected cells, disrupting genes that interfere with their potency and specificity and thereby generating a safer, more effective therapeutic product.

    Sangamo BioSciences specializes in the research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The company has ongoing phase 2 and phase 1/2 clinical trials to evaluate a novel ZFP Therapeutic for the treatment of HIV/AIDS. The company's other therapeutic programs are aimed at monogenic diseases such as hemophilia and hemoglobinopathies like sickle cell anemia. The company has agreed to a strategic collaboration with Shire for developing therapeutics for hemophilia and other monogenic diseases and has forged strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corp.

    For more information, visit the company's Web site at www.sangamo.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: SGMO
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • It is clear that most people do not understand what is going to happen when the SGMO method is approved.
    "we can target and regulate any gene in any cell in any organism"
    EL.
    Prove it once and it wil not be necessary to prove that you can do it for every single drug application.
    When the gates open expect things to happen quickly in the area of monogenic diseases. Multiples.
    Just one person's interpretation
    25 May 2012, 01:01 PM Reply Like
  • I forgot to mention.
    Think 'cures'
    25 May 2012, 01:06 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.